Condition: Crohn Disease · Infliximab · Perianal Fistula Due to Crohn's Disease · Sponsor: Asan Medical Center
This study will compare the efficacy and safety of TDM (therapeutic drug monitoring)-based infliximab (CT-P13, RemsimaTM) intravenous therapy compared with the standard infliximab (RemsimaTM) intravenous therapy for patients with active perianal fistulzing Crohn's disease.
This description comes directly from the study's public registry record.
Byong Duk Ye, MD, PhD · 82-2-3010-3181 · bdye@amc.seoul.kr
Eun Ja Youn, RN · 82-2-3010-8298 · eunja.soul@gmail.com
Always discuss trial participation with your own doctor first.
| Asan Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06051253